Related Experiment Video

Updated: Jul 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumonia in neonates: can it be managed in the community?

A T Bang1, R A Bang, V P Morankar

  • 1SEARCH, District Gadchiroli, India.

Archives of Disease in Childhood
|May 1, 1993
PubMed

Insights

Community health workers can safely manage neonatal pneumonia with co-trimoxazole, reducing deaths. This approach significantly lowers pneumonia mortality in infants, especially in the first two months of life.

Area of Science:

  • Pediatrics
  • Public Health
  • Infectious Diseases

Background:

  • Neonatal pneumonia is a leading cause of infant mortality globally, with approximately two million deaths annually.
  • The World Health Organization recommends hospitalization for all infant pneumonia cases within the first two months of life.
  • In India, neonatal pneumonia accounts for over half of pneumonia-related infant deaths, with parents often refusing referrals.

Purpose of the Study:

  • To evaluate the effectiveness and safety of community-based management of neonatal pneumonia using co-trimoxazole.
  • To assess the impact of community-based interventions on pneumonia-specific mortality rates in neonates and infants.

Main Methods:

  • A field trial was conducted in Gadchiroli, India, involving community health workers and traditional birth attendants.
  • Cases of neonatal pneumonia were managed with co-trimoxazole in a community-based setting.
  • Pneumonia-specific mortality rates were compared between an intervention area and a control area over two years.

Main Results:

  • Overall case fatality for neonatal pneumonia managed in the community was 15% (10/65), with 6% (3/52) in uncomplicated cases.
  • No deaths occurred in 56 infants aged 30-59 days treated for pneumonia.
  • The intervention area showed a 40% reduction in neonatal pneumonia mortality and an 80% reduction in mortality for infants aged 1-2 months compared to the control area.

Conclusions:

  • Community-based management of uncomplicated neonatal pneumonia and pneumonia in the second month of infancy using co-trimoxazole is safe and effective.
  • Community-based interventions can significantly reduce pneumonia-specific mortality in young infants.
  • This strategy offers a viable alternative to hospitalization for certain cases, improving access to care in resource-limited settings.

More Related Videos

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure05:50

International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure

Published on: March 12, 2020

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...